The transition from a paper to an electronic Trial Master File (TMF) system is a significant
task. In many cases, some pharma and biotech firms (sponsors) may find that they are in the late stages of digitising their TMF system resulting in some documents being left as hard copies. Ahead of the 2017 Trial Master File conference we examine the top challenges that are attached to operating trials with a late stage TMF.
Please note: That all fields marked with an asterisk (*) are required.
*Processing your payment may take a moment. Please click submit payment only once, and do not refresh this page. Doing so may result in your credit card being charged more than once.
Your experience on this site will be improved by allowing cookies.